Nature of Operations and Basis of Presentation - Additional Information (Details) - USD ($)													3 Months Ended		12 Months Ended		34 Months Ended
	May 30, 2023	Mar. 24, 2023	Jan. 30, 2023	Mar. 14, 2022	Mar. 04, 2022	Jan. 14, 2022	Oct. 12, 2021	Mar. 19, 2021	Jan. 25, 2021	Apr. 30, 2020	Mar. 18, 2020	Nov. 09, 2018	Mar. 27, 2023	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 24, 2023	Mar. 31, 2023	Jan. 31, 2023	Dec. 29, 2022	Aug. 19, 2022	Jun. 30, 2022	Oct. 04, 2021
Organization Consolidation and Presentation of Financial Statement [Line Items]
Accumulated deficit															$ 140,747,269	$ 114,509,954
Cash and cash equivalents															2,329,218	12,710,762
Net cash used in operating activities															(30,251,898)	(134,909)
Proceeds from issuance of common stock, net of issuance costs															8,909,718	3,139,047
Reimbursement payment								$ 14,000,000.0
Development payments								10,000,000.0
Current liabilities															18,951,700	$ 29,109,950
Deferred collaboration funding															8,400,000
Threshold equity value as per Nasdaq capital market listing standards															2,500,000
Threshold market value as per Nasdaq capital market listing standards															35,000,000
Threshold net income from continuing operations as per Nasdaq capital market listing standards															$ 500,000
Threshold number of business days for market value of listed securities															30 days
Threshold number of calendar days to regain compliance															180 days
Threshold bid price per share for continued listing on nasdaq																				$ 1.00
Public float																						$ 19,747,717
Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, net of issuance costs, shares		2,335,000
Proceeds from issuance of common stock gross		$ 2,700,000
Second Term Loan
Organization Consolidation and Presentation of Financial Statement [Line Items]
Proceeds from issuance of debt															$ 7,000,000.0
Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, net of issuance costs, shares															772,057	200,000
Proceeds from issuance of common stock gross															$ 1,100,000	$ 500,000
Number of shares, company may sell on any single business day										50,000
Maximum amount of Common stock at time of sale, per regular purchase										$ 1,000,000.0
Lincoln Park | Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Proceeds from issuance of common stock gross																	$ 4,000,000.0
Proposed Collaboration and License Agreement
Organization Consolidation and Presentation of Financial Statement [Line Items]
Upfront non-refundable payment received								1,000,000.0
Proposed Collaboration and License Agreement | Relief Therapeutics Holding AG
Organization Consolidation and Presentation of Financial Statement [Line Items]
Upfront non-refundable payment received									$ 1,000,000.0
Proposed Collaboration and License Agreement | Secured Loan | Relief Therapeutics Holding AG
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, term									12 months
Debt instrument, principal amount									$ 4,000,000.0
Debt instrument, interest rate									6.00%
Collaboration Agreement | Second Development Payment
Organization Consolidation and Presentation of Financial Statement [Line Items]
Deferred collaboration funding															$ 8,400,000
Collaboration Agreement | Relief Therapeutics Holding AG
Organization Consolidation and Presentation of Financial Statement [Line Items]
Upfront non-refundable payment received									$ 1,000,000.0
Cash payment received								10,000,000.0	10,000,000.0					$ 10,000,000.0
Reimbursement payment								14,000,000.0	14,000,000.0
Repayment of outstanding balance of prior loan and interest								4,000,000.0	$ 4,000,000.0
Development payments								$ 20,000,000.0
Proceeds from first tranche of development payments subject to new drug application							$ 5,000,000.0
Net profit split ratio based on territory								60.00%	60.00%
Net profit split ratio									60%:40%
Percentage of royalty net sales received								15.00%	15.00%
Milestone payment to be received								$ 6,000,000.0	$ 6,000,000.0
Collaboration Agreement | Relief Therapeutics Holding AG | First Development Payment
Organization Consolidation and Presentation of Financial Statement [Line Items]
Cash payment received														$ 10,000,000.0
Collaboration Agreement | Relief Therapeutics Holding AG | Second Development Payment
Organization Consolidation and Presentation of Financial Statement [Line Items]
Potential proceeds from development payments subject to acceptance of new drug																							$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application							5,000,000.0
Collaboration Agreement | Secured Loan | Relief Therapeutics Holding AG
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, term									12 months
Debt instrument, principal amount									$ 4,000,000.0
Debt instrument, interest rate									6.00%
Waiver and Agreement | Relief Therapeutics Holding AG
Organization Consolidation and Presentation of Financial Statement [Line Items]
Proceeds from second tranche of development payments subject to new drug application							5,000,000.0
Second tranche of development payment, expiry date						Jan. 14, 2022
Waiver and Agreement | Relief Therapeutics Holding AG | Second Development Payment
Organization Consolidation and Presentation of Financial Statement [Line Items]
Proceeds from first tranche of development payments subject to new drug application						$ 5,000,000.0	5,000,000.0
Proceeds from second tranche of development payments subject to new drug application							$ 5,000,000.0
Second tranche of development payment, expiry date						Jan. 14, 2022
SWK Credit Agreement | Lenders Party and SWK Funding LLC | Subsequent Event | SOFR
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, periodic payment, principal			$ 600,000
SWK Credit Agreement | Second Term Loan | Lenders Party and SWK Funding LLC | Scenario Forecast
Organization Consolidation and Presentation of Financial Statement [Line Items]
Minimum cash balance required by the loan covenants																		$ 3,000,000.0
SWK Credit Agreement | Second Term Loan | Lenders Party and SWK Funding LLC | Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Minimum cash balance required by the loan covenants			$ 1,500,000
SWK Credit Agreement | Second Term Loan | Lenders Party and SWK Funding LLC | Subsequent Event | Repayment Occurs On Or Before April 15, 2023
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument repayment percentage on outstanding principal amount			1.18%
SWK Credit Agreement | Second Term Loan | Lenders Party and SWK Funding LLC | Subsequent Event | Repayment Occurs On Or After April 16, 2023 But Prior to May 16, 2023
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument repayment percentage on outstanding principal amount			1.28667%
SWK Credit Agreement | Second Term Loan | Lenders Party and SWK Funding LLC | Subsequent Event | Repayment Occurs On Or After May 16, 2023 But Prior to June 16, 2023
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument repayment percentage on outstanding principal amount			1.39334%
SWK Credit Agreement | Second Term Loan | Lenders Party and SWK Funding LLC | Subsequent Event | Repayment Occurs On Or After June 16, 2023
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument repayment percentage on outstanding principal amount			1.50%
SWK Credit Agreement | Second Term Loan | Original Term Loan And Swk Loans | Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, principal amount																			$ 7,000,000.0
SWK Credit Agreement | Original Term Loan | Lenders Party and SWK Funding LLC
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, principal amount					$ 6,500,000
Debt instrument, frequency of periodic payment															quarterly
Origination fees				$ 100,000
Warrant issued to purchase common stock					150,000																100,000
Warrant, exercise price					$ 2.46																$ 1.51
SWK Credit Agreement | Original Term Loan | Lenders Party and SWK Funding LLC | SOFR
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, frequency of periodic payment															quarterly
SWK Credit Agreement | Original Term Loan | Lenders Party and SWK Funding LLC | Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, interest rate, increase			3.00%
Amortizing date of Principal payment			Apr. 15, 2023
Warrant issued to purchase common stock			250,000
Warrant, exercise price			$ 2.39
SWK Credit Agreement | Original Term Loan | Lenders Party and SWK Funding LLC | Subsequent Event | If ACER-001 Approval does not Occur on or Before December 31, 2022
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, maturity date			Mar. 04, 2024
Debt instrument repayment percentage on outstanding principal amount			150.00%
SWK Credit Agreement | Original Term Loan | Lenders Party and SWK Funding LLC | Subsequent Event | SOFR
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, interest rate			1.00%
Debt instrument, periodic payment, principal			$ 1,300,000
Debt instrument, basis spread on variable rate			11.00%
Amortizing date of Principal payment			May 15, 2023
Secured Convertible Note Purchase Agreement | Secured Convertible Notes | MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P.
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, principal amount					$ 6,000,000.0
Debt instrument, interest rate					6.50%
Debt instrument, frequency of periodic payment															quarterly
Debt instrument, interest rate, increase					11.50%
Conversion price					$ 2.50
Marathon Convertible Note Purchase Agreement | Marathon Convertible Notes | MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P.
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, principal amount					$ 6,000,000.0
Debt instrument, interest rate					6.50%
Debt instrument, frequency of periodic payment															quarterly
Conversion price					$ 2.50
Marathon Convertible Note Purchase Agreement | Marathon Convertible Notes | MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P. | Scenario Forecast
Organization Consolidation and Presentation of Financial Statement [Line Items]
Buy-Out percentage	212.50%
Marathon Convertible Note Purchase Agreement | Marathon Convertible Notes | MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P. | Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Number of business days for repurchase of convertible note			5 days
Buy-Out percentage			200.00%
Number of business days for payment in full of all senior indebtedness			5 days
Increase in Buy-Out percentage			0.2500
Marathon Credit Agreement | Marathon Convertible Notes | Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Termination agreement date													Jan. 30, 2023
Marathon Credit Agreement | Term Loan | Lender Party and Marathon
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, principal amount					$ 42,500,000
Debt instrument, interest rate					13.50%
Debt instrument, frequency of periodic payment															quarterly
Debt instrument, maturity date					Dec. 31, 2028
Percentage of option to capitalize				4.00%
Debt instrument, maturity date, description															The final maturity date of the Term Loan would be the earlier of six years after the Term Loan Funding Date or December 31, 2028.
Debt instrument amortization percentage					2.78%
Percentage of prepayment, prior to March 4, 2025					5.00%
Percentage of prepayment, on or after March 4, 2025, but prior to March 4, 2026					3.00%
Percentage of prepayment, on or after March 4, 2026, but prior to March 4, 2027					2.00%
Percentage of prepayment, on or after March 4, 2027					1.00%
Percentage of aggregate revenue as royalty payments					2.00%
Payment for commitment fees					$ 200,000
Payment for additional commitment fees					600,000
Royalty payments on aggregate revenue cap amount					$ 15,000,000.0
Termination agreement date			Jan. 30, 2023
Weighted Average | Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, gross sale price per share															$ 1.42	$ 2.47
Maximum
Organization Consolidation and Presentation of Financial Statement [Line Items]
Public float															$ 75,000,000
Maximum | Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Shares value might be issued under agreement										$ 15,000,000.0					$ 15,000,000.0
Number of shares, company may sell on any single business day										100,000
Maximum | Collaboration Agreement | Relief Therapeutics Holding AG
Organization Consolidation and Presentation of Financial Statement [Line Items]
Development payments								$ 20,000,000.0
Minimum | SWK Credit Agreement | Original Term Loan | Lenders Party and SWK Funding LLC | Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Proceeds from issuance of debt			$ 7,700,000
Minimum | Marathon Convertible Note Purchase Agreement | Marathon Convertible Notes | MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P. | Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Gross proceeds from issuance or sale of equity, debt and/or hybrid securities, loans or other financing			40,000,000.0
At-the-Market Facility
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, net of issuance costs, shares															3,312,471	877,107
Proceeds from issuance of common stock gross															$ 6,500,000	$ 2,800,000
Common stock offering costs															200,000	200,000
Proceeds from issuance of common stock, net of issuance costs															6,300,000	$ 2,600,000
Remained available under facility		$ 29,400,000													33,500,000		29,400,000
Amount remained available under facility															$ 33,500,000
At-the-Market Facility | Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, net of issuance costs, shares													1,462,254
Issuance of common stock, price per share													$ 2.81
Proceeds from issuance of common stock gross													$ 4,100,000				$ 20,600,000
Common stock offering costs													100,000
Proceeds from issuance of common stock, net of issuance costs													$ 4,000,000.0
At-the-Market Facility | Weighted Average
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, gross sale price per share															$ 1.9749	$ 3.1692
At-the-Market Facility | Weighted Average | Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, gross sale price per share													$ 2.81
At-the-Market Facility | Maximum
Organization Consolidation and Presentation of Financial Statement [Line Items]
Aggregate offering price of common stock											$ 50,000,000.0	$ 50,000,000.0
March 2023 Offering | SWK Credit Agreement | Original Term Loan | Lenders Party and SWK Funding LLC | Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Proceeds from issuance of common stock, net of issuance costs			$ 10,000,000.0
Pre-Funded Warrants | Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Warrant issued to purchase common stock		585,306															585,306
Common Warrants | Subsequent Event
Organization Consolidation and Presentation of Financial Statement [Line Items]
Warrant issued to purchase common stock		2,920,306															2,920,306